Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on November 14, 2019. The filing serves to announce the company's financial results for the three and nine months ended September 30, 2019. The registrant is incorporated in California and lists its common stock on the NYSE American.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references external documents for these details:
- Results of Operations: Referenced in the press release attached as Exhibit 99.1.
- Cash Balance and Operating Expenses: Referenced in a prospectus supplement dated November 13, 2019, filed on November 14, 2019.
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text body. It directs investors to the attached press release (Exhibit 99.1) and the prospectus supplement for the announcement of results and operating expenses for the quarter ended September 30, 2019.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing includes a standard disclaimer regarding forward-looking statements (using terms such as "may," "will," "believes," "plans," "intends," "anticipates," "expects," and "estimates").
- Risk Factors: The company states that additional factors that could cause actual results to differ materially from anticipated results are contained in its Form 10-K and Forms 10-Q under the heading "Risk Factors."
- Disclaimer: OncoCyte disclaims any intent or obligation to update forward-looking statements except as required by law.
- Legal Status of Information: Information in Item 2.02 and Exhibit 99.1 is deemed "furnished" and not "filed" under Section 18 of the Exchange Act, meaning it is not subject to the liability of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 14, 2019) for specific revenue, net loss, and operating expense figures for the three and nine months ended September 30, 2019.
- Examine the Prospectus Supplement dated November 13, 2019, for the specific cash balance as of September 30, 2019.
- Consult the most recent Form 10-K and 10-Q filings to understand the "Risk Factors" referenced in the forward-looking statements disclaimer.
- Verify the company's status as an Emerging Growth Company (indicated as "Yes" in the filing) and its election regarding extended transition periods for accounting standards.